Translating Evidence of HDL and Plaque Regression

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Atherosclerosis Research

Background:

• High-density lipoproteins (HDLs) are recognized for their atheroprotective effects.
• Preclinical and population studies indicate HDL's role in preventing cardiovascular disease.
• Early animal and clinical studies suggested HDL infusion could lead to plaque regression.

Purpose of the Study:

• To investigate the evolving role of HDL therapeutics in atherosclerosis.
• To evaluate the impact of HDL-targeting agents on atherosclerotic plaque.
• To address the disappointing outcomes of recent HDL studies in the context of statin therapy.

Main Methods:

• Review of preclinical evidence and population studies on HDL.
• Analysis of findings from HDL infusion studies in animal models.
• Examination of results from early and recent clinical imaging trials evaluating HDL agents and statin use.

Main Results:

• Preclinical data consistently support HDL's atheroprotective properties.
• Early HDL infusion studies showed evidence of plaque regression.
• Recent imaging studies involving HDL agents with high-intensity statins have produced disappointing results.

Conclusions:

• Despite early promise, the efficacy of HDL-targeting therapies in plaque regression requires further investigation.
• Advancements in imaging technology are crucial for evaluating HDL agents.
• The evolving understanding of plaque biology and HDL therapeutics presents new opportunities for research.